Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
3.39 ^USD	+0.89%		+9.35%	-44.88%

May. 30	Minerva Neurosciences, Inc. Announces Board Changes, Effective from August 6, 2024	CI
May. 01	Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Minerva Neurosciences, Inc. Enters into $15 Million Debt Facility with Oxford Finance LLC and Silicon Valley Bank

January 20, 2015 at 06:30 am EST

Minerva Neurosciences, Inc. announced it has entered into a $15 million debt facility with Oxford Finance LLC and Silicon Valley Bank. The financing positions Minerva to broaden and advance the clinical development program for MIN-101, the company's investigational compound in development for the treatment of schizophrenia.

Latest news about Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. Announces Board Changes, Effective from August 6, 2024	May. 30	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27	MT
Top Midday Decliners	Feb. 27	MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 27	MT
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.	Feb. 27	MT
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback	Feb. 27	DJ
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug	Feb. 27	DJ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	Feb. 27	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
HC Wainwright Adjusts Price Target on Minerva Neurosciences to $11 From $8, Maintains Neutral Rating	23-08-02	MT
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
Sector Update: Health Care Stocks Declining Late Wednesday	23-06-28	MT
Sector Update: Health Care	23-06-28	MT
Top Midday Gainers	23-06-28	MT
Minerva Neurosciences to Raise $20 Million Through Private Placement of Common Shares	23-06-28	MT
Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding	23-06-26	CI
Transcript : Minerva Neurosciences, Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
Minerva Neurosciences Says US FDA Accepts Filing of New Drug Application for Roluperidone to Treat Schizophrenia Symptoms	23-05-10	MT
Minerva Neurosciences Gets FDA Confirmation for NDA for Roluperidone	23-05-10	DJ
Minerva Neurosciences, Inc. Announces Board Changes	23-05-05	CI

Chart Minerva Neurosciences, Inc.

Duration

Period

More charts

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.39 USD

Average target price

7 USD

Spread / Average Target

+106.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MINERVA NEUROSCIENCES, INC.	-44.88%	23.71M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs